Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16171 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Charlotte R L Greene und 8 weiteren Autor:innen. Beteiligte Einrichtung: Usher Institute, University of Edinburgh, Edinburgh, UK. Hauptthemen laut MEDLINE: Antipsychotic Agents, Diabetes Mellitus, Type 2, Antidepressive Agents, Practice Patterns, Physicians'. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Prescribing of antidepressant and antipsychotic drugs in general populations has increased in the United Kingdom, but prescribing trends in people with type 2 diabetes (T2D) have not previously been investigated. The aim of this study was to describe time trends in annual prevalence of antidepressant and antipsychotic drug prescribing in adult patients with T2D.
Methods
We conducted repeated annual cross‐sectional analysesof a population‐based diabetes registry with 99% coverage, derived from primary and secondary care data in Scotland, from 2004 to 2021. For each cross‐sectional calendar year time period, we calculated the prevalence of antidepressant and antipsychotic drug prescribing, overall and by sociodemographic characteristics and drug subtype.
Results
The number of patients with a T2D diagnosis in Scotland increased from 161 915 in 2004 to 309 288 in 2021. Prevalence of antidepressant and antipsychotic prescribing in patients with T2D increased markedly between 2004 and 2021 (from 20.0 per 100 person‐years to 33.3 per 100 person‐years and from 2.8 per 100 person‐years to 4.7 per 100 person‐years, respectively). We observed this pattern for all drug subtypes except for first‐generation antipsychotics, prescribing of which remained largely stable. The degree of increase, as well as the overall prevalence of prescribing, differed by age, sex, socioeconomic status and subtype of drug class.
Conclusions
There has been a marked increase in the prevalence of antidepressant and antipsychotic prescribing in patients with T2D in Scotland. Further research should identify the reasons for this increase, including indication for use and the extent to which this reflects increases in incident prescribing rather than increased duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Usher Institute, University of Edinburgh, Edinburgh, UK.
- MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
- Institute of Health Informatics, University College London, London, UK.
ORCID-Profile: Charlotte R L Greene
Zitieren
APA
Greene, C. R. L., Blackbourn, L. A. K., McGurnaghan, S. J., Mercer, S. W., Smith, D. J., Wild, S. H., Wu, H., Jackson, C. A., & Scottish Diabetes Research Network epidemiology group (2024). Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16171
Vancouver
Greene CRL, Blackbourn LAK, McGurnaghan SJ, Mercer SW, Smith DJ, Wild SH, et al. Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16171
BibTeX
@article{Greene2024,
author = {Greene, Charlotte R L and Blackbourn, Luke A K and McGurnaghan, Stuart J and Mercer, Stewart W and Smith, Daniel J and Wild, Sarah H and Wu, Honghan and Jackson, Caroline A and Scottish Diabetes Research Network epidemiology group, Scottish Diabetes Research Network epidemiology group},
title = {Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16171}
}
EUVIMED